Agios Pharmaceuticals | AGIO - Operating Profit


Agios Pharmaceuticals reported $-110.02M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Arrowhead Research USD -141.26M 182.07M Mar/2026
Astellas Pharma JPY 185.36B 136.79B Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Daiichi Sankyo JPY 85.1B 4.44B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 251.34M 15.43M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Incyte USD 700.4M 376.22M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 667M 4.32B Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026